Alexander Chi, M.D.

Education:

1994-1998:  University of Virginia, B.S. Chemistry with a biological specialization, Charlottesville, VA

1998-2002:  Virginia Commonwealth University, M.D., Richmond, VA

Postdoctoral Training:

Research Fellowships

2003-2004:  Department of Human Oncology, University of Wisconsin, Madison, WI

Internship

2004-2005:  Internal Medicine, University of Maryland-Franklin Square Hospital Center, Baltimore, MD

Residency

2005-2009:  Radiation Oncology, Loyola University Medical Center, Maywood, IL

Externships

02/2010:  Division of Thoracic Radiotherapy, Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX

04/2011:  Division of Thoracic Radiotherapy, Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX

Medical License and Board Certification:

May 2009:  State of Illinois (036123539)

Sept 2009:  State of Arizona (42422)

May 2012:  State of West Virginia (24863)

Feb 2016:  State of New York (283169)

May 2016:  State of Virginia (0101260178)

May 2016:  State of Michigan (4301109891)

Aug 2016:  State of Wisconsin (66043)

June 2010:  Board Certification in Radiation Oncology (American Board of Radiology)

Academic and Hospital Appointments:

2009-2011:  Assistant Professor, Dept. of Radiation Oncology, University of Arizona, Tucson, AZ

2012-2015:  Assistant Professor, Dept. of Radiation Oncology, West Virginia University, Morgantown, WV

2016-2017:  Consulting physician, Associate Professor, Dept. of Radiation Oncology, Shanghai Proton and Carbon Ion Center, Shanghai, China

2017-2018:  Consultant Physician, Dept. of Radiation Oncology, Marshfield Clinic, Eau Claire, WI

Current:  Chair, Department of Radiation Oncology
Nanjing Xianlin Drum Tower Hospital, an affiliate of Mt. Sinai Medical
Center in New York, Nanjing, Jiangsu, China

Clinical Activities:

2009-Present

Clinical expertise: thoracic and head & neck radiotherapy with advanced technology. I specialize in the clinical utilization and implementation of image guided, intensity-modulated radiotherapy (IG-IMRT), and stereotactic ablative radiotherapy (SABR) in the treatment of thoracic and head & neck malignancies.

I have extensive experience with volumetric-modulated arc therapy (VMAT), and Helical Tomotherapy (HT). I also have experience in intensity modulated (beam scanning) proton and carbon ion radiotherapy. I have published a number of studies in peer-reviewed journals on head & neck and thoracic radiotherapy.

In addition, I have experience in staff training and the building of new radiation oncology programs.

Research experience: I have experience in both laboratory based translational research and clinical research/clinical trials. My overall research focus is clinical and translational research to further personalize lung cancer and head & neck cancer treatments. While I was a fellow at UW-Madison, I investigated the resistance mechanism of various cancer cell lines to EGFR inhibition. This led to the publication of one study in Clinical Cancer Research as a co-author. As an assistant professor of Radiation Oncology at West Virginia University, I furthered my clinical research in more individualized treatment for localregionally confined non small cell lung cancer (NSCLC). I was the principal investigator (PI) for two early phase clinical trials that focused on local therapy for stage I – III non-small cell lung cancer (NSCLC), and translational studies to identify valid predictive biomarkers for treatment response to high dose irradiation. While at Marshfield Clinic, I continued to pursue biomarker research and population based studies in the area of localized NSCLC.

At West Virginia University, I received internal grants and recognition from external funding agencies. In 2013, I was selected to attend the ASCO/AACR Methods in Clinical Cancer Research Workshop. In the same year, I was awarded a pilot grant from the American Cancer Society administered through WVU in the area personalized radiotherapy for local-regionally confined NSCLC and the identification of predictive biomarkers for failure after such treatment. In 2015, I received a score of Excellent on my ACS Research Scholar Grant application focusing on translational research in individualized lung cancer therapy for local-regionally confined lung cancer.

I have been on ASCO’s scientific meeting committee for the localregional lung cancer track for 2017-2019. I am the track leader for this committee for the 2019 annual meeting and the session chair for the oral presentation session.

Scope of Practice:  IGRT, IMRT, and SBRT, and the building of treatment programs. While with expertise in advanced thoracic and head & neck radiotherapy, I am experienced in the treatment of other anatomical sites with advanced technology as well.

Scientific and Medical Societies:

2005-2011:  Radiological Society of North America

2005-Present:  American Society of Therapeutic Radiology and Oncology

2005-Present:  American Society of Clinical Oncology

2006-2009:  American Brachytherapy Society

2007-2011:  European Society for Radiotherapy and Oncology

2009-Present:  International Association on Studies of Lung Cancer

2010-Present:  International Geriatric Radiotherapy Group

2013-Present:  American Association for Cancer Research

Publications (peer reviewed articles):

  1. Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, Harari PM. Establishment and characterization of a model of acquired resistance to Epidermal Growth Factor Receptor targeting agents in human cancer cells. Clin Cancer Res 2009; 15: 1589-92.
  2. Gao M, Albuquerque K, Chi A, Rusu I. 3D CT-based volumetric dose assessment of 2D plans using GEC-ESTRO guidelines for cervical cancer brachytherapy. Brachytherapy 2009; 9: 55-60.
  3. Chi A, Gao M, Nguyen NP, Albuquerque K. Technical aspects of the integration of Three-Dimensional treatment planning dose parameters (GEC-ESTRO working group) into pre-implant planning for LDR gynecological interstitial brachytherapy. Technol Cancer Res Treat 2009; 8: 181-186.
  4. Chi A, Gao M, Sinacore J, Nguyen NP, Vali F, Albuquerque K. Single vs. customized treatment planning for Image-guided HDR brachytherapy for cervical cancer: Dosimetric comparison & predicting factor for OAR overdose with a single plan approach. Int J Radiat Oncol Biol Phys 2009; 75: 309-314.
  5. Nguyen NP, Almeida FS, Chi A, Nguyen LM, Cohen D, Karlsson U, Vinh-Hung V. Molecular Biology of Breast Cancer Stem Cells: Potential Clinical Applications. Cancer Treat Rev 2010; 36: 485-491.
  6. Nguyen NP, Ceizyk M, Almeida F, Chi A, Betz M, Moderrasifar H, Sroka T, Cohen D, Jang S, Abraham D, Stevie M, Smith-Raymond L, Krafft S, Vinh-Hung V. Effectiveness of Image-guided Radiotherapy for Locally Advanced Rectal Cancer. Ann Surg Oncol 2010, 18: 380-385.
  7. Nguyen NP, Chi A, Nguyen L, Hong-Ly B, Karlsson U, Vinh-Hung V. Human Papillomavirus-associated Oropharyngeal Cancer: a New Clinical Entity. QJM 2010; 103: 229-236.
  8. Chi A, Komaki R. Management of Brain Metastasis from Lung Cancer: A comprehensive review. Cancers 2010; 2: 2100-2137.
  9. Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic Review of the Patterns of Failure Following Stereotactic Body Radiation Therapy in Early-Stage Non-Small-Cell Lung Cancer: Clinical Implications. Radiother Oncol 2010; 94: 1-11.
  10. Chi A, Tomé WA, Fowler J, Komaki R, Nguyen NP, Mehta MP, Welsh JS. Stereotactic Body Radiation Therapy in Non-Small-Cell Lung Cancer: Linking Radiobiological Modeling and Clinical Outcome. Am J Clin Oncol 2010; 34: 432-441.
  11. Chi A, Jang SY, Welsh JS, Nguyen NP, Komaki R. The feasibility of stereotactic body radiation therapy delivered by Tomotherapy in centrally located lesions. Int J Radiat Oncol Biol Phys 2010; 81: 856-862.
  12. Nguyen NP, Abraham D, Dessai A, Davis R, Sroka T, Chi A, Gelumbauskas S, Ceizyk M, Smith-Raymond L, Jang S, Hamilton R, Vinh-Hung V. Impact of image-guided radiotherapy to reduce laryngeal edema following treatment for non-laryngeal and nonhypopharyngeal head and neck cancer. Oral Oncol 2011; 47: 900-904.
  13. Nguyen NP, Vok J, Sroka T, Khan R, Jang S, Chi A, Betz M, Ewell L, Cohen D, Vo RP, Mills M, Vinh-Hung V. Feasibility of image-guided radiotherapy based on tomotherapy for the treatment of locally advanced anal carcinoma. Anticancer Res 2011; 31: 4393-4396.
  14. Chi A, Liao Z, Nguyen NP, Howe C, Gomez D, Jang SY, Komaki R. Intensitymodulated radiotherapy after extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Onc 2011; 6: 1132-1141.
  15. Chi A, Nguyen NP, Xu J, Ji M, Tang J, Jin J, Ong ES, Welsh JS. Correlation of three different approaches of small bowel delineation and acute lower gastrointestinal toxicity in adjuvant pelvic intensity-modulated radiation therapy for endometrial cancer. Technol Cancer Res Treat 2012; 11: 353-359.
  16. Nguyen NP, Vock J, Chi A, Ewell L, Vos P, Mills M, Khan R, Almeida F, Davis R, Betz M, Jang S, Gelumbauskas S, Vo RP, Vinh-Hung V. Effectiveness of intensity-modulated and image-guided radiotherapy to spare the mandible from excessive radiation. Oral Oncol 2012; 48: 653-657.
  17. Chi A, Liao Z, Nguyen NP, Xu J, Welsh JS, Jang SY, Howe C, Komaki R. Dosimetric Selection for Helical Tomotherapy Based Stereotactic Ablative Radiation Therapy for Early Stage Non-Small Cell Lung Cancer or Lung Metastases. PLoS One 2012; 7:e35809.
  18. Nguyen NP, Vos P, Vinh-Hung V, Ceizyk M, Smith-Raymond L, Stevie M, Slane B, Chi A, Desai A, Krafft SP, Jang S, Hamilton R, Karlsson U, Abraham D. Feasibility of image-guided radiotherapy based on helical tomotherapy to reduce contralateral parotid dose in head and neck cancer. BMC Cancer 2012; 12: 175.
  19. Nguyen NP, Vock J, Chi A, Vinh-Hung V, Dutta S, Ewell L, Jang S, Betz M, Almeida F, Miller M, Davis R, Sroka T, Vo RP, Karlsson U, Vos P. Impact of intensity-modulated and image-guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer. Strahlenther Onkol 2012; 188: 677-685.
  20. Nguyen NP, Vock J, Vinh-Hung V, Almeida F, Ewell L, Betz M, Jang S, Vo RP, Dutta S, Godinez J, Karlsson U, Chi A. Effectiveness of prophylactic retropharyngeal lymph node irradiation in patients with locally advanced head and neck cancer. BMC Cancer 2012; 12: 253.
  21. Nguyen NP, Chi A, Betz M, Almeida F, Vos P, Davis R, Slane B, Ceizyk M, Abraham D, Smith-Raymond L, Stevie M, Jang S, Gelumbauskas S, Vinh-Hung V. Feasibility of intensity-modulated and image-guided radiotherapy for functional organ preservation in locally advanced laryngeal cancer. PLoS One 2012; 7:e42729.
  22. Chi A, Remick S, Tse W. EGFR inhibition in non-small cell lung cancer: current evidence and future directions. Biomarker Research 2013; 1: 2.
  23. Chi A, Nguyen NP, Tse W, Sobremonte G, Concannon P, Zhu A. Optic pathway preservation with intensity modulated radiotherapy for sinonasal malignancies. J Hem Oncol 2013; 6: 4.
  24. Chi A, Ma P, Fu G, Hobbs G, Wen S, Jang SY, Welsh JS, Nguyen NP, Dai J, Jin J, Komaki R. Critical structure sparing in stereotactic ablative radiotherapy for central lung lesions: Helical Tomotherapy vs. Volumetric Modulated Arc Therapy. PLoS One 2013;
    8: e59729.
  25. Nguyen NP, Ceizyk M, Vos P, Betz M, Chi A, Almeida F, Davis R, Slane B, Gelumbauskas S, Smith-Raymond L, Abraham D, Stevie M, Jang S, Vinh-Hung V. Feasibility of tomotherapy-based image-guided radiotherapy for locally advanced oropharyngeal cancer. PLoS One 2013; 8: e60268.
  26. Nguyen NP, Ceizyk M, Vock J, Vos P, Chi A, Vinh-Hung V, Pugh J, Khan R, Truong C, Albala G, Locke A, Karlsson U, Gelumbauskas S, Smith-Raymond L. Feasibility of image-guided radiotherapy for elderly patients with locally advanced rectal cancer. PLoS One 2013; 8: e71250.
  27. Nguyen NP, Kratz S, Lemanski C, Vock J, Vinh-Hung V, Gorobets O, Chi A, Almeida F, Betz M, Khan R, Godinez J, Karlsson U, Ampil F. Image-guided radiotherapy for locally advanced head and neck cancer. Front Oncol 2013; 3: 172.
  28. Chi A, Wen S, Liao Z, Fowler J, Xu J, Nguyen NP, Welsh JS, Komaki R. What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer. Biomed Res Int 2013; 2013: 391021.
  29. Nguyen NP, Nguyen ML, Vock J, Lemanski C, Kerr C, Vinh-Hung V, Chi A, Khan R, Woods W, Altdorfer G, D’Andrea M, Karlsson U, Hamilton R, Ampil F. Potential applications of imaging and image-guided radiotherapy for brain metastases and glioblastoma to improve patient quality of life. Front Oncol 2013; 3: 284.
  30. Nguyen NP, Shen W, Kratz S, Vock J, Vos P, Vinh-Hung V, Altdorfer G, Ewell L, Jang S, Karlsson UL, Godinez J, Mills M, Sroka T, Dutta S, Chi A. Feasibility of tomotherapy-based image-guided radiotherapy for small cell lung cancer. Front Oncol 2013; 3: 289.
  31. Nguyen NP, Jang S, Vock J, Vinh-Hung V, Chi A, Vos P, Pugh J, Vo RA, Ceizyk M, Desai A, Smith-Raymond L; International Geriatric Radiotherapy Group. Feasibility of intensity-modulated and image-guided radiotherapy for locally advanced esophageal cancer. BMC Cancer 2014; 14: 265.
  32. Chi A, Yu J, Rojanasakol Y, Monga M, Tse W, Remick S. Acquired resistance to EGFR inhibition in non-small cell lung cancer. Minerva Pneumo 2014; 53: 9 14.
  33. Nguyen ML, Willows B, Khan R, Chi A, Kim L, Nour SG, Sroka T, Kerr C, Godinez J, Mills M, Karlsson U, Altdorfer G, Nguyen NP, Jendrasiak G; International Geriatric Radiotherapy Group. The potential role of magnetic resonance spectroscopy in imageguided radiotherapy. Front Oncol 2014; 4: 91.
  34. Chi A, Nguyen NP, Komaki R. Image guidance in the delivery of stereotactic ablative radiation therapy in patients with centrally located early stage non-small cell lung cancer or lung metastases. Front Oncol 2014; 4: 151.
  35. Chi A, Nguyen NP, Welsh JS, Tse W, Monga M, Oduntan O, Almubarak M, Rogers J, Remick SC, Gius D. Strategies of dose escalation in the treatment of locally advanced non-small cell lung cancer: image guidance and beyond. Front Oncol 2014; 4: 156.
  36. Chi A, Nguyen NP. 4D FDG-PET based treatment planning for IGRT in the treatment of lung cancer. Front Oncol 2014; 4: 205.
  37. Nguyen NP, Vock J, Vinh-Hung V, Khan R, Slane B, Sroka T, Jang S, Dias V, Vo RA, Karlsson U, Chi A. Feasibility of tomotherapy for postoperative irradiation of lower extremity sarcomas. Tumori 2014; 100: 476-479.
  38. Chi A, Nguyen NP. The utility of positron emission tomography in the treatment planning of image-guided radiotherapy for non-small cell lung cancer. Front Oncol 2014; 4: 273.
  39. Lemanski C, Thariat J, Ampil F, Bose S, Vock J, Davis R, Chi A, Dutta S, Woods W, Desai A, Godinez J, Karlsson UL, Nguyen NP, Vinh-Hung V. Feasibility of imageguided radiotherapy for cardiac sparing in patients with left-sided breast cancer. Front Oncol 2014; 4: 257.
  40. Nguyen NP, Ries T, Vock J, Vos P, Chi A, Vinh-Hung V, Thompson S, Desai A, Sroka T, Vo RA, Gelumbauskas S, Hamilton R, Kalsson U, Mignault A; the International Geriatric Radiotherapy Group. Effectiveness of radiotherapy for elderly patients with non-melanoma skin cancer of the head. Geriatr Gerontol Int. 2015; 15: 601-605.
  41. Nguyen NP, Kratz S, Chi A, Vock J, Vos P, Shen W, Vinh-Hung V, Ewell L, Jang S, Altdorfer G, Karlsson U, Godinez J, Woods W, Dutta S, Ampil F, and the International Geriatric Radiotherapy Group. Feasibility of image-guided radiotherapy and concurrent chemotherapy for locally advanced non-small cell lung cancer. Cancer Investigation 2015; 33: 53 – 60.
  42. Nguyen NP, Davis RD, Bose S, Dutta S, Vinh-Hung V, Chi A, Godinez J, Desai A, Woods W, Altdorfer G, D’Andrea M, Karlsson UL, Sroka T. Potential applications of image-guided radiotherapy for radiation dose escalation in patients with early stage highrisk prostate cancer. Front Oncol 2015; 5: 18.
  43. Dutta S, Nguyen NP, Vock J, Kerr C, Godinez J, Bose S, Jang S, Chi A, Almeida F, Woods W, Desai A, Davis R, Kalsson UL, Altdorfer G. Image-guided radiotherapy and brachytherapy for cervical cancer. Front Oncol 2015; 5: 64.
  44. Chi A, Wen S, Monga M, Almubarak M, Tse W, Remick S, Nguyen NP. Chest wall dose assessment in stereotactic ablative radiotherapy delivered with volumetric modulated arc therapy for peripheral lung tumors. Cancer Treat Res Comm 2016；9：5 – 14.
  45. He X, Despeaux E, Stueckle T, Chi A, Castranova V, Dinu C, Wang L, Rojanasakul Y. Nanotube-induced carcinogenic transformation of human bronchial epithelial cells. AJP Lung Cell Mol Physiol 2016; 311: L538-549.
  46. Nguyen NP, Nguyen LM, Sroka T, Hong-Ly B, Chi A, Vos P, Karlsson U, Vinh-Hung V. Oral sex and oropharyngeal cancer: the role of the primary care physician. Medicine 2016; 95: e4228.
  47. Chi A, Wen S, Monga M, Almubarak M, He X, Rojanasakul Y, Tse W, Remick SC. Definitive upfront stereotactic ablative radiotherapy combined with image guided, intensity modulated radiotherapy (IG-IMRT) or IG-IMRT alone for locally advanced non-small cell lung cancer. PLoS One 2016; 11: e0162453.
  48. Nguyen NP, Godinez J, Shen W, Vinh-Hung V, Gorobets H, Thariat J, Ampil F, Vock J, Karlsson U, Chi A. Is surgery indicated for elderly patients with early stage non-small cell lung cancer, in the era of stereotactic body radiotherapy? Medicine 2016; 95: e5212.
  49. Zhao J, Chi A, Mao R, Hu G, Ji M. Serum amyloid p-component level may be a biomarker for lung toxicities and overall survival after thoracic radiotherapy for nonsmall cell lung cancer. Clin Lab 2016; 62: 2183 – 2190.
  50. Chi A, Chen H, Wen S, Yan H, Liao Z. Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: a systematic review and hypothesis-generating meta-analysis. Radiother Oncol 2017; 123: 346 – 354.
  51. Chi A, Lin L, Wen S, Yan H, Hsi WC. Comparison of photon volumetric modulated arc therapy, intensity modulated proton therapy, and intensity modulated carbon ion therapy for delivery of hypo-fractionated thoracic radiotherapy. Radiat Oncol 2017; 12: 132.

Manuscripts under preparation/review:

Editorial:

  1. Chi A, Wen S, Nguyen NP, Jacobson G, Remick S, Tse W, Liao Z. Extra-pleural pneumonectomy in the setting of tri-modality therapy for patients with malignant pleural mesothelioma. Chin J Cancer Res 2013; 25: 128-129.

Book chapters:

  1. Chi A, Nguyen NP, Komaki R. The management of brain metastases with a focus on radiotherapy. In Horizons in Cancer Research. Watanabe HS, editor. Nova Science Publishers, Hauppauge, NY. 2012; 46: 1-24.
  2. Nguyen NP, Almeida F, Chi A, Betz M, Vinh-Hung V. Locally advanced laryngeal carcinoma: Current issues and management. In Horizons in Cancer Research. Watanabe HS, editor. Nova Science Publishers, Hauppauge, NY. 2012; 46: 169-182
  3. Jacobson G, Chi A, Wang D, Devlin P, Buzorovic I, Damato A, O’Farrell D, Stewart AJ. Radiation oncology: concepts and techniques. In Textbook of Surgical Oncology. Balch CM/Morita S, editors. McGraw Hill Education, New York, NY. 2017

Abstracts:

  1. Qi X (Chi A), Byford A, Matherne GP. Dilated Cardiomyopathy Associated with Transgenic Over-expression of Cardiac A1 Adenosine Receptors. Poster Discussion. Children’s Medical Center 9th Annual Research Day, May, 1997.
  2. Papineni S, Chi A, Dryer S, et al. Unicentric Plasma Cell Variant Castleman’s Disease. Poster. American College of Physicians Maryland Chapter’s 22nd Mulholland-Mohler Maryland Associates Scientific Meeting, May, 2005.
  3. Chi A, Wolff M. A Case of Facial Nerve Palsy Caused by Mastoiditis. Poster. American College of Physicians Maryland Chapter’s 22nd Mulholland-Mohler Maryland Associates Scientific Meeting, May, 2005.
  4. Gao M, Albuquerque K, Chi A, Rusu I. Translation of Point Doses from Radiographbased Plans to 3D Volumetric Assessment Using GEC-ESTRO Guidelines for Cervical Cancer Brachytherapy. Poster. American Brachytherapy Society 28th Annual Meeting, Chicago, IL, May, 2007.
  5. Chi A, Gao M, Albuquerque K. 3D-Image-Based Treatment Planning for Gynecological Interstitial Brachytherapy(IB) with GEC-ESTRO WORKING GROUP Recommended Dose Volume Parameters: Initial Experience. Oral Presentation (Travel Award). American Brachytherapy Society 28th Annual Meeting, Chicago, IL, May, 2007.
  6. Chi A, Gao M, Vali F, Albuquerque K. Single vs. customized treatment planning fo multi-fraction intracavitary HDR brachytherapy for cervical cancer: do we need to take the extra step? Oral Presentation. 1st World Congress of Brachytherapy, Boston, MA, May, 2008.
  7. Chi A, Yun J, Osipo C, Rizzo P, Sabou A, Albuquerque K, Miele L. The additive effects of gamma secretase inhibitors and radiation in MDA-MD-231 breast cancer cell lines. Abstract. Proceedings of the ASCO annual meeting. Chicago, IL, May, 2008.
  8. Chi A, Gao M, Vali F, Albuquerque K. Dose to critical organ when using single vs. customized treatment planning for multi-fractional HDR brachytherapy and its correlation with applicator position. Poster. 50th ASTRO annual meeting, Boston, MA, Sept, 2008.
  9. Chi A, Gao M, Albuquerque K. Dose to GEC-ESTRO defined high risk CTV and Organs at risk with CT-based single vs. customized treatment planning for multifractional intracavitary HDR brachytherapy. Oral presentation (not able to attend). 1st Sino-American Networking in Radiation Oncology Meeting, Beijing, China, Aug, 2008.
  10. Chi A, Rychlik K, Millbrandt L, Roeske J, Albuquerque K. Intensity modulated Radiation Therapy (IMRT): its toxicities and efficacy in treating endometrial cancer. Poster. American Radium Society’s annual meeting, Vancouver BC, Canada, April, 2009.
  11. Chi A, Xu J, Sinacore J, Rychlik K, Millbrandt L, Warfel B, Roeske J, Albuquerque K. Small bowel volume in postoperative IMRT for endometiral cancer and acute lower GI toxicity: separate loops vs. bowel space. Poster. ECCO 15/ ESMO 34, Berlin, Germany, Sept, 2009, Berlin, Germany.
  12. Chi A, Lien-Chun Lin, Sijin Wen, Haijuan Yan, Wen Chien His. Photon volumetric modulated arc therapy (VMAT) vs. intensity modulated proton therapy (IMPT) vs. intensity modulated carbon ion therapy (IMCIT) in the delivery of hypo-fractionated thoracic radiotherapy. Poster. 2017 Multidisciplinary Thoracic Cancers Symposium, San Francisco, USA, March 16-18, 2017.
  13. He X, Chi A, Wang L, Rojanasakul Y. Nrf2 confers radioresistance by regulating cancer stem trait in lung cancer cell line. Poster. American Association for Cancer Research Annual Meeting, Washington DC, USA, April 1-5, 2017.

Honors and Awards:

2007 Travel Award, American Brachytherapy Society Annual Meeting

2009 American Brachytherapy Society Fellowship in high dose rate brachytherapy. Texas Cancer Clinic. San Antonio, TX

2013 ASCO/ AACR Workshop on Methods in Clinical Cancer Research, Vail, CO

2015 Mountaineer Leadership Development Institute, West Virginia University

Teaching:

2009-2011:  Teaching of residents during their regular lung and head & neck rotations. University of Arizona.

2012:  Medical Oncology fellows’ teaching rounds to discuss the role of radiotherapy, and especially IMRT in the treatment of esophageal cancer. West Virginia University.

2012:  Lecture on ACRO Guidelines on the responsibilities of the Radiation Oncologist, Medical Physicist, Dosimetrist, and Radiation Therapist in the development of a SBRT program. Dept of Radiation Oncology at West Virginia University.

2012:  Radiotherapy student lecture on SABR and the application of advanced technology in NSCLC. Dept of Radiation Oncology at West Virginia University

2013:  Technical Guidelines on the patient selection and personnel responsibilities for the Medical Physicist. Dept of Radiation Oncology at West Virginia University.

2013:  Stereotactic ablative radiotherapy for non-small cell lung cancer, Lecture for Radiotherapy Students.

2013:  Visiting Fellow from Shanghai Chest Hospital in Shanghai, China.

2012-2015:  Participating in Medical Students and Medical Oncology Fellows’ elective rotations.

Invited Lectures/ Presentations:

2012 Invited Speaker, “Stereotactic body radiation therapy for early stage NSCLC”, Annual gala of the Mary Babb Randolph Cancer Center, White Sulphur Springs, WV, May, 2012.

2012 Invited Speaker, “Stereotactic body radiation therapy for early stage NSCLC and lung metastases”, Pulmonary Medicine Grand Rounds, WVUH, Morgantown, WV, Aug, 2012.

2012 Invited Speaker, “Image guided stereotactic ablative radiotherapy for early stage non-small cell lung cancer”, 38th Annual Hal Wanger Family Medicine Conference, WVUH, Morgantown, WV, Sept 21, 2012.

2012 Invited Speaker, “Management of oropharyngeal cancer with a focus on technical advances”, Grand Rounds, Dept. of Otolaryngology, WVUH, Morgantown, WV, Sept 26, 2012.

2013 Invited Speaker, “Stereotactic ablative radiotherapy for early stage NSCLC”, West Virginia Medical Society, Morgantown, WV, Jan 8, 2013.

2013 Invited Speaker, “Image-guided stereotactic ablative radiotherapy for early stage non-small cell lung cancer”, Allen Lung Cancer Program of the Mary Babb Randolph Cancer Center, Morgantown, WV, Feb 22, 2013.

2013 Invited Speaker, “Stereotactic ablative radiotherapy in the treatment of non-small cell lung cancer”, 23rd Annual Fall Cancer Conference of the Mary Babb Randolph Cancer Center, Morgantown, WV, Oct 14, 2013.

2016 Invited lecturer. Stereotactic body radiation therapy for localized nonsmall cell lung cancer. Tsinghua Chang Gung Hospital, Beijing, China.

2018 Annual meeting highlights for the local-regional lung cancer/other track for fellows and trainees.

2018 Best of ASCO, Lung Cancer-Non-small cell local-regional/Small cell/Other track: Faculty.

2019 When the rubber meets the road: challenges of immunotherapy treatment in NSCLC. Faculty for this ASCO education session during the ASCO’s annual meeting.

2019 Annual meeting highlights for the local-regional lung cancer/other track for fellows and trainees.

Committee Assignments:

2010-2011 Radiation Safety Committee, University of Arizona, Tucson, AZ

2012-2015 Protocol Research Monitoring Committee, West Virginia University, Morgantown, WV

2012-2015 Tenure and Promotion Committee, Radiation Oncology, West Virginia University, Morgantown, WV

2012-2015 Allen Lung Cancer Program, West Virginia University, Morgantown, WV

Committees for Professional Associations:

2016- Present:  Member, ASCO Scientific Program Committee’s Lung Cancer – Nonsmall cell local-regional/ Small cell/ Other track.

2016 – 2019:  ASCO Scientific Program Committee’s Lung Cancer-Non-small cell local-regional/ Small cell/ Other track.
– Track leader for the 2019’s annual meeting.
– Session Chair for oral presentations during the 2019 annual
meeting.

2017- Present:  Member, Eastern Cooperative Oncology Group (ECOG) Thoracic Committee.

Editorial Service:

2013-Present:  Editorial Board. Biomarker Research

2013-Present:  Editorial Board. Austin Journal of Cancer and Clinical Research

Journal Review:

2011 Acta Oncologica

2011 Radiation Oncology

2012 International Journal of Radiation Oncology, Biology, and Physics

2012 Cancers

2012 Technology in Cancer Research and Treatment

2012 American Journal of Clinical Oncology

2012-Present PLoS ONE

2012-Present Radiotherapy and Oncology

2013-Present Journal of Hematology Oncology

2015-Present Journal of Radiation Oncology

2016 Thoracic Cancer

2017 Head & Neck

Grant Review:

2012-Present: Catalan Agency for Health Information Assessment and Quality

Languages:

Spoken: English, Chinese

Studied: French

Research Funding:

PAST

American Cancer Society Institutional Research Grant #09-061-04

Stereotactic ablative radiotherapy (SABR) for T2 and microscopic T3 (PL3), N0, M0 nonsmall cell lung cancer (NSCLC) and predictive biomarkers for metastasis and radiation pneumonitis after SABR

This is a prospective phase II study evaluating the efficacy of delivering 75 Gy in 10 daily fractions for the treatment of more than T1 early stage NSCLC and the potential biomarkers for treatment response and distant metastasis in the tumor tissue and blood.

Pending/Applied:

Title: Stereotactic boost combined with concurrent chemoradiation for locally advanced nonsmall cell lung cancer.

Title: Biomarker-driven lung cancer radiotherapy combining targeted therapy, immuno-therapy and stereotactic ablative radiotherapy.

Title: GDF15: a predictive biomarker for biomarker-driven lung cancer radiotherapy

Studies with Institutional Review Board approval, PI: Chi

Retrospective

  1. Clinical outcome of definitive treatment of non-small cell lung cancer: The West Virginia Experience

Prospective

  1. A phase II study of stereotactic ablative radiotherapy (SABR) for T2 and microscopic T3 (PL3), N0, M0 non-small cell lung cancer (NSCLC) and predictive biomarkers for metastasis and radiation pneumonitis after SABR
  2. A phase I dose escalation study of a Hypofractionated Stereotactic Boost (HySBst) to the primary site in patients with stage II-III non-small cell lung cancer